TRDA

Rating neutralTentativeAI Memo

Entrada Therapeutics

As of 2026-10-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ENTR-601-44 open-label follow-up • 2026-12-31

Base target: $5 / p=45% prob

Biggest risk

The 5 mg/kg cohort was small, its mean dystrophin increase was 0.10%, and no functional benefit was observed. Higher-dose efficacy and tolerability remain unproven; two serious treatment-emergent adverse events in one participant resolved [#8-K-2026-10-14] SEC Exhibit 99.1. No verified post-readout analyst rating or target revisions were found.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The October ENTR-601-45 readout met its primary safety objective, and higher-dose DMD studies plus partnered VX-670 offer multiple ways to improve the clinical thesis. Management expects greater dystrophin production at higher doses, but that remains unproven [#8-K-2026-10-14] SEC Exhibit 99.1.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-17

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ENTR-601-44 higher-dose Cohort 2 data
ENTR-601-45 higher-dose Cohort 2 readout
The October ENTR-601-45 readout met its primary safety objective, and higher-dose DMD studies plus partnered VX-670 offer multiple ways to improve the clinical thesis.

BearKey bullets

Cash declined from $295.7 million at December 31, 2025 to $223.0 million at June 30, 2026; financing or dilution risk rises if spending persists or trials expand [#SEC-10Q-2026-08-05].
Higher doses or longer exposure may reveal safety issues; one Cohort 1 participant experienced two serious treatment-emergent adverse events that resolved [#8-K-2026-10-14].
No observed functional benefit in the initial ENTR-601-45 cohort; its small sample and low dystrophin response limit efficacy inference [#8-K-2026-10-14].

WatchKey bullets

ENTR-601-44 open-label follow-up

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=45%)

Target spread vs base: +67% / -58%

Scenario probabilities

Bull Target: $8 (p=25%)Base Target: $5 (p=45%)Bear Target: $2 (p=30%)

Commentary

The company characterized the October 14 readout as positive, but TRDA fell 6.4% that day and closed October 16 at $4.37, roughly 10.1% below its October 13 close historical prices. The trading pattern is consistent with skepticism about the modest biomarker response, though the price data alone do not establish its cause. Verified post-readout analyst revisions were unavailable. Numeric sentiment, options, short-interest and employee measures were unavailable; zeros denote missing data, not neutral readings.

As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ENTR-601-44 higher-dose Cohort 2 data
ENTR-601-45 higher-dose Cohort 2 readout

Scenarios

Bull Target (Scenario probability)

$8 / p=25% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
ENTR-601-44 open-label follow-up
Entrada expects Cohort 1 open-label safety and functional data by year-end 2026. The readout could clarify whether early functional signals persist with longer dosing; an inconclusive result would leave efficacy uncertain [#SEC-8K-2026-08-05].
Prob 75.00% • Move 25.00% • Priced-in 25.00%
EVENT2026-12-31
Partnered VX-670 Phase 1/2 results
Entrada said Vertex expected to report data from its VX-670 study in myotonic dystrophy type 1 in the second half of 2026. This is a separate pipeline test, but timing and disclosure remain under Vertex's control [#SEC-8K-2026-08-05].
Prob 65.00% • Move 15.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ENTR-601-44 higher-dose Cohort 2 data
2027-03-31
The company expects 12 mg/kg Cohort 2 data in Q1 2027. Safety, dystrophin production and functional measures could materially change the assessment of its exon-44 program [#SEC-8K-2026-08-05].
Prob 70% • Move 30% • Priced-in 20%
ENTR-601-45 higher-dose Cohort 2 readout
2027-06-30
After Cohort 1 showed a 0.10% mean dystrophin increase at 5 mg/kg but no observed functional benefit, Entrada expects 10 mg/kg Cohort 2 data in H1 2027. Whether higher dosing produces a meaningful biomarker and functional response is the key unresolved question [#8-K-2026-10-14] SEC Exhibit 99.1.
Prob 70% • Move 35% • Priced-in 20%

Risks

Cash declined from $295.7 million at December 31, 2025 to $223.0 million at June 30, 2026; financing or dilution risk rises if spending persists or trials expand [#SEC-10Q-2026-08-05].
Higher doses or longer exposure may reveal safety issues; one Cohort 1 participant experienced two serious treatment-emergent adverse events that resolved [#8-K-2026-10-14].
No observed functional benefit in the initial ENTR-601-45 cohort; its small sample and low dystrophin response limit efficacy inference [#8-K-2026-10-14].
Trial timing, dose escalation, regulatory interactions and partner-controlled VX-670 disclosure may change.

Peers

Symbol	Summary
DYN	Dyne is a direct clinical DMD exon-skipping comparator, but its program maturity makes it an imperfect valuation peer Dyne SEC exhibit.
SRPT	Sarepta provides a DMD exon-skipping clinical and regulatory reference, not a like-for-like small-cap valuation benchmark given its commercial portfolio Sarepta release.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-17

Loading AI feed…

Symbol

Summary

DYN

Dyne is a direct clinical DMD exon-skipping comparator, but its program maturity makes it an imperfect valuation peer Dyne SEC exhibit.

SRPT

Sarepta provides a DMD exon-skipping clinical and regulatory reference, not a like-for-like small-cap valuation benchmark given its commercial portfolio Sarepta release.